# LL2-10 digest — Ch10 Bisphenol A: contested science, divergent safety evaluations

*Late lessons from early warnings II* (EEA 2013), pp. 215–239 (main text pp. 215–229). Authors: Andreas Gies (German Federal Environment Agency, UBA) and Ana M. Soto (Tufts). **No panels.** The summary's reference to a panel on animal carcinogen testing (p. 215) is a copy error from Ch8 (Panel 8.2, pp. 194–196).

## Core story

- **Origins.** BPA's oestrogenic activity was found in the 1930s by the team that later produced DES. Unsuitable as a medicine, it became the building block of polycarbonate (1957) and epoxy resins. Production reached 3.8 Mt a year by 2006 (p. 216).
- **Exposure.** BPA leaches from polycarbonate, can linings, thermal paper, dental sealants and medical devices, so exposure is near-universal (p. 216).
- **Rediscovery by accident.** In 1993 Stanford endocrinologists traced an oestrogenic contaminant to their autoclaved polycarbonate labware. No screening programme had flagged BPA (p. 217).
- **The evidence split.** From 1997 academic studies reported low-dose developmental effects in rodents; Table 10.1 lists 49 at ≤50 μg/kg bw/day (pp. 219, 227–228). EFSA and the FDA relied on a few industry-sponsored GLP guideline studies (Tyl et al., 2002, 2008) that reported none. The chapter says low-dose differences in the rat study were dismissed by its authors, and an "independent" study (Ryan et al., 2010) also found no low-dose effects. EFSA and the EU risk assessment report excluded the academic studies for few doses, small samples, weak statistics or inconsistency (pp. 220–221).
- **Divergent verdicts on largely shared evidence:**
  - EFSA set a TDI of 50 μg/kg (p. 221);
  - by the authors' own arithmetic, the Nordic minority's studies imply 0.13 μg/kg and the NTP's data 0.008 μg/kg (p. 222);
  - Canada listed BPA as toxic on evidence it called "limited" (p. 222);
  - the FDA's Science Board called the FDA's margins "inadequate"; the FDA voiced "some concern" but kept its number (pp. 222–223);
  - ANSES found effects below reference doses (p. 223);
  - EFSA reaffirmed safety in 2010 (p. 223).
- **Internal dose.** Measured free BPA in maternal blood is 4–6 ng/ml; model estimates are 0.1–10 pg/ml (p. 224).
- **Influence (pp. 225, 228).** A consultancy with tobacco-industry history claimed credit for EU classification as Category 3 rather than Category 2. Nine of 21 EFSA panel members declared industry-linked ties. Funding tracked outcomes: 94 of 104 government-funded studies found harm, versus 0 of 11 industry-funded.
- **Markets moved first.** Pressure from consumers and politicians forced product withdrawals while agencies still said "safe" (p. 225). The EU banned BPA baby bottles from 2011 (p. 226).

## Authors' lessons and recommendations

- **Lessons:**
  - a "same old story" of deployment before understanding (p. 226);
  - monotonic dose-response fails for hormone-like agents, and "the time makes the poison" (pp. 218–219);
  - BPA is not simply a "weak oestrogen" (p. 229);
  - GLP compliance "does not indicate that good science has been performed" (Box 10.1, p. 220);
  - excluding all non-guideline studies "cannot be defensible" (p. 223).
- **Recommendations:**
  - restart the EU assessment, led by the high-impact researchers (p. 226);
  - "Until final decisions are made", end BPA uses involving close contact via food or the environment (p. 226);
  - an industry-financed, government-managed testing fund;
  - academic results not to be outweighed by contract-lab results;
  - updated guidelines and stronger adviser independence (p. 229).

## Main mechanisms

- **Paradigm defence:** findings dismissed as implausible under old assumptions (p. 220).
- **Evidence-selection rules as the battleground** (p. 223, fn 2).
- **Ossified test endpoints** (pp. 222–223, 229).
- **Latency defeating epidemiology** (p. 219).
- **Hidden stocks and unknown uses** (p. 216).
- **Structural funding conflicts and procedural advocacy** (pp. 225, 229).
- **Markets outrunning regulators** (p. 225).

## Transferable insights (technology-neutral)

1. Known hazardous properties may not follow a substance into new uses (pp. 216–217, 220). *Moderate.*
2. Formal screening can miss what serendipitous research finds (p. 217). *Moderate.*
3. Methods that assume monotonic scaling can yield artefactual "no effect" results (pp. 218–221). *Moderate.*
4. Evidence-eligibility rules can move "safe" levels by orders of magnitude on the same evidence (pp. 221–223). *Strong* for the pattern; the extreme ratios are the authors' own calculations.
5. Process assurance is not scientific adequacy (p. 220). *Moderate.*
6. Validation lag discounts newer, more sensitive measures (pp. 222, 229). *Moderate.*
7. With latent, transient exposure, epidemiology struggles to detect harm, so demanding human proof risks waiting until harm is irreversible (p. 219). *Strong* for the latency mechanism, given the DES precedent. *Moderate* for the normative corollary, which is an inference beyond the chapter.
8. Funding source correlates with findings (p. 228). *Moderate*: small, protagonist-compiled sample.
9. Advocacy targets classification chokepoints (p. 225). *Suggestive*: self-reported.
10. Market and public pressure can outpace assessments (p. 225). *Moderate.*
11. The most exposed (neonates) are the least visible (p. 224). *Moderate.*
12. Institutions sharing evidence reach divergent verdicts (pp. 222–223). *Strong* for the divergence. *Moderate* for the causes: only assessment stage and study criteria are evidenced (fn 2, p. 223).

## Main caveats

- **Protagonist authors, no dissenting panel.** Soto co-authored many sources, including the Chapel Hill statement, which the chapter lists among the assessments while noting it "is not a risk assessment in the classical sense". The UBA view cited is Gies's own agency's.
- **Framing outruns the evidence.** The report calls BPA a "false negative" (p. 10), yet the chapter concedes that cross-sectional associations "are not a proof of causation" (p. 226). Its other human associations are listed without that caveat.
- **"Overlap" holds only at the margins.** Animal effect doses overlap human intake only where the lowest-dose studies (0.2–2.5 μg/kg) meet upper-percentile or worst-case intakes (up to 11–13 μg/kg in young children). Typical adult intakes are lower (pp. 224–225, 227).
- **No precaution standard.** The summary promises to address "challenges for applying the precautionary principle" (p. 215), but the chapter never says what weight of evidence should trigger action.
- **Overstatements:** "far-reaching agreement" (p. 219) versus acknowledged dispute (p. 218); "irrefutable" (p. 220); "over 800" toxic studies (p. 223) versus "at least 46" (p. 221).
- **Selective handling of counter-evidence:** failed replications are unengaged (Ashby 1999 is even listed as positive); Teeguarden et al. 2011 (free BPA undetectable in serum) is cited but undiscussed; the chapter's own contamination warning (p. 216) is not applied to the high serum values.
- **Errors:** the Tyl AGD finding differs between text (male increase) and table (female decrease), and Tyl reported a female increase; the cited letter concerns ovary weights. Braun 2009 is a cohort, not cross-sectional. Figure 10.1's inverted-U caption fits only two of its four panels: (a) has its largest effect at the highest dose and (b) peaks at the lowest (p. 218).
- **Silent on benefits, alternatives and substitution risk.**
- **Hindsight.** EFSA's 2023 TDI of 0.2 ng/kg bw/day (verified) moved strongly in the direction the chapter urged. But CLARITY-BPA reproduced the guideline-versus-academic split, and the BfR opposed EFSA, so the conflict did not resolve.